Valbiotis Stock
The Valbiotis stock is trending slightly upwards today, with an increase of €0.004 (0.540%) compared to yesterday's price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Valbiotis stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Valbiotis in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Valbiotis vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Valbiotis | 0.540% | - | - | - | - | - | - |
| Cerenis Therapeutics Holding S.A. | 0.110% | -0.106% | -6.995% | 31.111% | -44.956% | 58.923% | 77.444% |
| Sensorion SA | -1.430% | 7.500% | 19.957% | - | - | - | - |
| Genoway S.A. Inh. | 0.000% | -1.271% | 6.393% | -20.205% | -6.048% | -36.339% | -39.244% |
News
VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission
VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission
VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63
VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63
VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M